RNA Interference Therapy Market
RNA Interference Therapy Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
RNA Interference Therapy Market Size and Growth
The RNA Interference Therapy market is poised for significant growth, with an estimated market size reaching approximately $5 billion by 2026. Increasing prevalence of genetic disorders and advancements in therapeutic applications are driving demand. Key players are focusing on innovative delivery mechanisms and enhanced efficacy, shaping competitive dynamics in the sector.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ "Silence Therapeutics"
◍ "Arrowhead Pharmaceuticals"
◍ "Janssen Research & Development"
◍ "Sylentis"
◍ "Sirnaomics"
◍ "Dicerna Pharmaceuticals"
◍ "Alnylam Pharmaceuticals"
◍ "Silenseed"
◍ "Vir Biotechnology"
◍ "OliX Pharmaceuticals"
◍ "Bio-Path Holdings"
◍ "Suzhou Ribo Life Science"
The RNA interference therapy market is competitive, with companies like Alnylam Pharmaceuticals pioneering treatments. Firms such as Silence Therapeutics and Arrowhead Pharmaceuticals focus on innovative delivery systems. Collaborations and advancements in therapeutic applications drive market growth. Sales revenues include:
- Alnylam Pharmaceuticals: $900 million (2022)
- Dicerna Pharmaceuticals: $210 million (2021)
- Bio-Path Holdings: $8 million (2021).
Request Sample Report
Market Segmentation
By Application By Product
◍ "Cancer Treatment"
◍ "Hereditary Disease"
◍ "Infectious Disease"
◍ "Nervous System Disease"
◍ "Diseases of Immune System"
◍ "Cardiovascular Disease"
◍ "Metabolic Disease"
◍ "siRNA"
◍ "miRNA" ◍ "shRNA" ◍ "piRNA"
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
